References
- Brundage M, Gropp M, Mefti F et al. Health-related quality of life in recurrent platinum-sensitive ovarian cancer – results from the CALYPSO trial. Ann. Oncol. doi:10.1093/annonc/mdr583 (2012) (Epub ahead of print).
- Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J. Clin. Oncol. 28(20), 3323–3329 (2010).
- Marth C, Alexandre J, Hanker LC et al. Pegylated liposomal doxorubicin and carboplatin (C-PLD) versus paclitaxel and carboplatin (C-P) in platinum-sensitive ovarian cancer (OC) patients (pts): treatment at recurrence and overall survival final analysis from CALPYSO Phase III GCIG trial. J. Clin. Oncol. 29(Suppl.), (2011) (Abstract 5052).
- von Gruenigen VE, Huang HQ, Gil KM, Frasure HE, Armstrong DK, Wenzel LB. The association between quality of life domains and overall survival in ovarian cancer patients during adjuvant chemotherapy: a Gynecologic Oncology Group Study. Gynecol. Oncol. 124(3), 379–382 (2012).
- Grover S, Hill-Kayser CE, Vachani C, Hampshire MK, DiLullo GA, Metz JM. Patient reported late effects of gynecological cancer treatment. Gynecol. Oncol. 124(3), 399–403 (2012).
- Chase DM, Wenzel L. Health-related quality of life in ovarian cancer patients and its impact on clinical management. Expert Rev. Pharmacoecon. Outcomes Res. 11(4), 421–431 (2011).